Kexing Biopharm's innovative drug "GB19 Injection" received approval from NMPA to conduct clinical trials in China
Recently, Kexing Biopharm's innovative drug "GB19 Injection" for the treatment of systemic lupus erythematosus (SLE) received approval from National Medical Products Administration (NMPA) to conduct clinical trials in China. Differentiated Innovative Targeting Mechanism GB19 Injection targets BDCA2, a receptor specifically expressed on the surface of plasmacytoid dendritic cells (pDCs). Its mechanism of action is distinct from that of currently approved therapies that primarily targeting the B-cell pathway. By specifically binding to BDCA2, GB19 inhibits the production of type I interferon by pDC cells, thereby modulating the pathogenic feedback loop between innate and adaptive immunity. In preclinical studies, GB19 demonstrated high potency, favorable bio...
